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Abstract
Background—Chronic kidney disease leads to complex metabolic changes and an increased risk 
of fracture. Currently, calcitriol is the standard of care as it effectively suppresses parathyroid 
hormone levels in CKD patients. While calcitriol and its analogues improve BMD and reduce 
fractures in the general population, the extension of these benefits to patients with advanced 
kidney disease is unclear. Here, the impact of calcitriol on the skeleton was examined in the 
setting of reduction in parathyroid hormone.
Methods—Male Cy/+ rats, a PKD-like CKD model, were treated with either vehicle or calcitriol 
for five weeks. Their normal littermates served as controls. Animals were assessed for changes in 
mineral metabolism and skeletal parameters (microCT, histology, whole bone mechanics, and 
bone quality).
Results—PTH levels were significantly higher (12-fold) in animals with CKD compared to 
normal controls. CKD animals also exhibited negative changes in bone structural and mechanical 
properties. Calcitriol treatment resulted in a 60% suppression of PTH levels in animals with CKD. 
Despite these changes, it had no impact on bone volume (cortical or cancellous), bone turnover, 
osteoclast number, or whole bone mechanical properties.
Conclusions—These data indicate that while calcitriol effectively lowered PTH in rats with 
CKD, it did little to prevent the negative effects of secondary hyperparathyroidism on the 
skeleton.
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INTRODUCTION
Chronic kidney disease—mineral and bone disorder (CKD-MBD) represents a 
conglomeration of various metabolic and skeletal changes, such as hyperphosphatemia, 
secondary hyperparathyroidism, and an increased fracture risk [1-3]. Currently, the primary 
goal of therapy is the suppression of elevated levels of parathyroid hormone (PTH) [4]. For 
FDA approval, the standard end point for the treatment of secondary hyperparathyroidism 
has been a reduction of PTH by 30% or more [5-6]. Due to a paucity of data (detailed in the 
Kidney Disease Improving Global Outcomes guidelines), the impact of these levels of 
suppression on vascular and skeletal outcomes is unclear [3,7-8].
Though imperfect, serum PTH is considered a surrogate biomarker for underlying renal 
osteodystrophy [9-11]. Calcitriol, vitamin D analogues, and calcimimetics all lower PTH, 
but data assessing their efficacy on bone are rather limited. While most osteoporosis clinical 
studies in non-CKD patients demonstrate that calcitriol reduces fracture risk through 
improvements in BMD [12-13], the extension of these benefits to patients with advanced 
kidney disease where cortical bone is adversely affected is unclear [4]. Preclinical studies 
using calcium to suppresss PTH to normal (or below) levels largely preserves skeletal 
properties [14-17]. Unfortunately, this effectiveness comes at the cost of increased vascular 
calcification, at least when hypercalcemia ensues. These data are consistent with concerns 
raised in CKD patients about the use of calcium supplementation and calcium-based 
phosphate binders [18-23].
In light of these data, a more thorough examination of the effects of calcitriol therapy on 
specific skeletal outcomes seems warranted. Despite widespread use clinically, there are 
limited calcitriol intervention studies in humans and animal models that examine tissue 
properties (histomorphometry, trabecular architecture, cortical geometry, etc.). Fracture 
prevention studies have not been conducted for calcitriol in patients with CKD and limited 
preclinical studies have evaluated mechanical properties of bone with intervention. The goal 
of the current study was to fill these voids in a preclinical model of CKD. Specifically, we 
sought to investigate how suppression of PTH levels with calcitriol would impact skeletal 
properties using an animal model of progressive chronic kidney disease.
METHODS
Animal Model
Cy/+ rats are characterized by autosomal dominant cystic disease [24]. These animals have a 
mutation (R823W) in Anks6, a gene that codes for the protein SamCystin. The exact 
function of this protein is unknown [25], but unlike many other cyst-related proteins, 
SamCystin does not localize to the primary cilia of kidney cells [26]. Recently, this gene 
was shown to be responsible for nephronophthisis in humans [27]. In this rat model, the 
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mutation leads to a slow and gradual onset of CKD [24]. It parallels the human condition 
through the progressive development of hyperphosphatemia, secondary 
hyperparathyroidism, and vascular calcification. Blood urea nitrogen (BUN) and creatinine 
are elevated by 20 weeks of age. Skeletal abnormalities consistent with osteitis fibrosa 
cystica are present by 30 weeks.
Experimental Design
At 24 weeks, male Cy/+ rats were placed on a casein diet (Purina AIN-76A; 0.7% Pi, 0.6% 
Ca), which we have shown to produce a more consistent kidney disease phenotype [24]. At 
this point, these animals have reached their full adult weights. Starting at 25 weeks of age, 
Cy/+ rats were treated with vehicle (n=9) or calcitriol (n=11) (10 ng/kg 3x weekly; 
intraperitoneal) for 5 weeks. This treatment duration was chosen as it approximates an 
average bone remodeling cycle in skeletally mature rats (roughly six months in humans) and 
has been shown to be sufficient to detect treatment-induced skeletal changes in this model 
[28-29]. Based on preliminary studies in these animals, calcitriol doses were chosen to 
achieve approximately 50% suppression of PTH levels. Non-affected male littermates 
served as controls (n=8). All rats were injected with calcein (10 mg/kg; subcutaneous) 14 
and 4 days prior to sacrifice to label surfaces with active bone formation.
At 30 weeks of age, animals were anesthetized with isoflurane and underwent cardiac 
puncture for blood draw followed by exsanguination and bilateral pneumothorax to ensure 
death. The lumbar spine, tibiae, and femora were removed and stored at −20°C for analysis. 
All procedures were approved by and carried out according to the rules and regulations of 
the Indiana University School of Medicine’s Institutional Animal Care and Use Committee. 
Some of the data from normal and CKD-VEH animals have been published previously as 
these control groups were part of a larger study of which calcitriol treatment was one sub-
group [54].
Biochemistry
Blood plasma at 30 weeks was analyzed for BUN, calcium, and phosphorus using 
colorimetric assays (Point Scientific, Canton, MI, or Sigma kits). Intact PTH was 
determined by ELISA (Alpco, Salem, NH).
MicroCT
Using microCT (Skyscan 1172), trabecular architecture was determined from the metaphysis 
of the proximal tibia and the full length of the L4 vertebra. Cortical bone geometry was 
determined from the femoral midshaft. Cortical thickness was assessed at 75% of the height 
of the vertebra (from cranial to caudal) because this represents a region free of 
zygapophyseal attachment. All bones were wrapped in parafilm to prevent drying and 
scanned at a resolution of 12 μm in accordance with standard guidelines [30].
Histomorphometry
Static and dynamic histomorphometric measures were obtained from the proximal 
metaphysis of the tibia as well as the caudal metaphysis of the L3 vertebra. Histological 
processing followed previously used protocols from this lab [31-33]. Tissues were 
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embedded in methyl methacrylate for undecalcified sections. Transverse sections from the 
proximal tibia and frontal sections from the caudal portion of the L3 vertebra were cut and 
left unstained for dynamic histomorphometry or stained with with tartrate-resistant acid 
phosphatase (TRAP) for osteoclast measurements (tibia only). For cancellous bone, a region 
of interest approximately 0.8 mm from the growth plate that was analyzed. Unstained 
sections were assessed for total bone surface, single-labeled surface, and double-labeled 
surface to calculate mineral apposition rate (MAR), percent mineralizing surface (MS/BS), 
and bone formation rate (BFR/BS). TRAP-stained sections were assessed for bone surface, 
osteoclast number, and osteoclast surface to calculate the number of osteoclasts per unit 
bone surface (N.Oc/BS) and percent osteoclast surface (Oc.S/BS). All histomorphometric 
nomenclature follows standard usage [34].
Whole Bone Mechanics
Structural mechanical properties of femora were determined by four-point bending. The 
anterior surface was placed on two lower supports located +/−9 mm from the mid-diaphysis 
(18 mm span length) with an upper span length of 6 mm. Specimens were loaded to failure 
at a rate of 2 mm/min. Structural mechanical properties were obtained directly from the 
force-displacement curves, while apparent material properties were derived from the force-
displacement curves, cross-sectional moments of inertia (Iml), and the distances from the 
centroid to the tensile surface using standard beam-bending equations for four-point bending 
[35].
Structural mechanical properties of L4 vertebrae were determined by uniaxial compression. 
Vertebra height was assessed from microCT images. Prior to mechanical testing, the 
vertebral arch and endplates were removed o create parallel surfaces for compression 
testing. Specimens were loaded at a rate of 0.5 mm/min. Structural mechanical properties 
were obtained directly from the force-displacement curves, while apparent material 
properties were derived from the force-displacement curves, pre-test sample heights, and the 
average bone area of five microCT slices (10%, 30%, 50%, 70%, and 90% slices of the pre-
test sample height) using equations for uniaxial compression [36-37].
Tissue Composition
The anteromedial portion of the tibial mid-diaphysis was polished with a 0.05 μm alumina 
suspension in order to create a flat region for spectroscopy and indentation testing. 
Composition was assessed using a LabRAM HR 800 Raman Spectrometer (HORIBA 
JobinYvon, Edison, NJ). A 660 nm laser was focused on the bone surface using a 50X 
objective to a spot size of ~10 μm. Three locations were imaged ~3 mm apart with five 20 
second acquisitions at each location as previously published [38]. A five-point linear 
baseline correction was applied in LabSpec 5 (HORIBA JobinYvon). Using OriginPro 8.6 
(OriginLab, Northampton, MA), a single Gaussian peak was fit to the PO43−ν1 peak, and the 
areas under the PO43−ν1, CO32−ν1, and Amide I peaks were calculated at each location. 
Type B carbonate substitution was found by the band area ratio of CO32−ν1/PO43−ν1. The 
degree of matrix mineralization 3- was determined by the band area ratio of PO43−ν1/Amide 
I. Mineral maturity (crystallinity) was determined by the inverse of the full width at half 
maximum (FWHM) of the PO43−ν1 peak.
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Nanoindentation
After Raman spectroscopy, nanoindentation was performed on the same samples using a 
Hysitron TI950 TriboIndenter. Samples were partially submerged in ultrapure water with the 
surface remaining uncovered for optical imaging of the surface to determine indentation 
locations but then fully submerged during testing. Locations were imaged using in situ 
scanning probe imaging. Then, 6 indentations were performed on a 10 μm × 20 μm grid, 
avoiding interactions from neighboring indentations. A previously calibrated fluid cell 
Berkovich diamond probe was used for the indentations. Machine calibrations were 
performed at the beginning of each day of testing. Tests were conducted in load control with 
a 10s loading period, a 10s hold at 3000 μN, and a 10 s unloading period. From the resulting 
load-displacement profiles, the indentation elastic modulus and hardness were calculated 
according to the following equations:
where Er is the reduced indentation elastic modulus of the sample, A is contact area, hc is the 
contact displacement, S is the stiffness of the sample determined from 40-95% of the 
unloading slope, H is the hardness of the sample, and Pmax is the peak force. All of the 
individual indentations (n=6 per location) were averaged to produce a single value for each 
location, and each of these locations was averaged to produce a single value for each 
sample.
Statistics
Comparisons among groups were assessed by one-way ANOVA with Fisher’s LSD post-hoc 
tests. A priori α-levels were set at 0.05 to determine significance.
RESULTS
Mineral Metabolism
Animals with CKD had higher serum levels of BUN compared to normal littermates. Serum 
calcium was normal, while phosphorus and PTH levels were significantly higher than their 
normal counterparts (Table 1). Animals treated with calcitriol had BUN, calcium, and 
phosphorus values similar to their untreated CKD counterparts. PTH levels in calcitriol 
animals were significantly lower than untreated CKD animals (−61%) but still higher than 
normal controls (+381%).
MicroCT
Vehicle-treated CKD animals had lower trabecular bone volume than normal animals at the 
proximal tibia. A similar pattern was observed in the vertebra. In both cases, animals treated 
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with calcitriol displayed no differences than their CKD-vehicle counterparts (Figure 1 and 
Table 2). All other trabecular parameters were similar between calcitriol animals and the 
untreated CKD animals.
Cortical bone of the femoral midshaft and lumbar vertebra was also negatively affected by 
CKD. CKD animals had lower cortical area, cortical thickness, and bending moments of 
inertia compared to normal controls (Table 2). Animals treated with calcitriol displayed 
cortical values similar to CKD-vehicle animals. Calcitriol did not correct CKD-induced 
changes in cortical area, thickness, porosity, or polar moment of inertia of the femur or 
cortical thickness of the vertebra (Table 2).
Histology
Vehicle-treated CKD animals had higher trabecular bone formation rates in the tibia and 
vertebra as well as higher osteoclast number and percent osteoclast surface than their normal 
counterparts (Figure 2 and Table 3). Calcitriol animals displayed similar values to CKD-
vehicle animals with regard to mineral apposition rate, osteoclast number, and percent 
osteoclast surface. While animals with calcitriol had a slightly higher proportion of 
mineralizing surfaces than CKD-vehicle animals (in the tibia only), bone formation rates at 
both sites were similar between these groups.
Whole Bone Mechanics
Animals with CKD had lower femoral ultimate force, stiffness, and energy to fracture 
compared to normal animals (Figure 3 and Table 4). Estimated material properties revealed 
a significantly lower modulus of toughness in CKD animals (Figure 3) with no differences 
in the ultimate stress or elastic modulus (Table 4). Animals treated with calcitriol displayed 
no treatment effects compared to vehicle-treated CKD. They were similar with regard to 
ultimate force, stiffness, and energy to fracture (Figure 3). Calcitriol treatment also had no 
effect on estimated material properties (Table 4).
Vertebral compression tests, which assess both trabecular and cortical bone, revealed that 
CKD animals had lower ultimate force and energy to ultimate force but no differences in 
stiffness compared to normal animals (Figure 3). Estimated material properties were similar 
among all three groups. As above, vertebrae from calcitriol animals were no different than 
their untreated CKD counterparts.
Bone Quality
Compared to normal controls, animals with CKD were found to have no differences in 
indentation properties. Calcitriol had no affect on these properties either (Table 5). Tissue 
composition assessed by Raman spectroscopy revealed no differences in any of the 
compositional parameters among the groups either.
DISCUSSION
The goal of this study was to assess the impact of PTH suppression on CKD-induced bone 
disease. Using calcitriol, the current standard of care in patients with secondary 
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hyperparathyroidism, PTH levels were suppressed by 60% in animals with CKD. Despite 
this reduction, no skeletal benefits were observed. This is likely due in part to the failure of 
calcitriol to suppress bone formation rates and osteoclast formation, both of which remained 
significantly higher than normal in long bones and vertebrae. These data raise important 
questions regarding how much PTH suppression is needed to produce skeletal benefits in the 
setting of CKD and whether PTH is an accurate biomarker of bone remodeling and 
mechanical properties.
In animal studies using calcitriol and paricalcitol in the 5/6th or 7/8th nephrectomy model the 
results on bone have been mixed (Table 6) [39-42]. Even in the presence of PTH 
suppression, only Jokihaara et al showed positive bone outcomes [39]. In that study, 8-
week-old animals underwent 5/6 nephrectomy and were treated with paricalcitol for 15 
weeks. Levels of PTH suppression were similar to the current study, and femoral neck BMD 
and mechanical properties were higher than CKD animals and equivalent to normal animals. 
Yet, no beneficial effects were observed in BMD or mechanical properties at the femoral 
diaphysis (a site assessed in the current study). While variations in these models may explain 
some of the skeletal differences, one possible explanation is that calcitriol has a preferential 
effect at certain skeletal sites. Although the femoral neck is a clinically relevant site, why it 
would be positively affected when the proximal tibia, femoral diaphysis, and lumbar 
vertebra in the current study were not is unclear.
Despite the plethora of data showing the effectiveness calcitriol and its analogues to 
suppress PTH in patients with advanced CKD [4,43-46], far fewer clinical studies have 
examined the impact of these treatments on bone outcomes (Table 7). As reviewed in the 
KDIGO CKD-MBD guidelines, the evidence supporting a skeletal benefit of calcitriol or its 
analogs is weak [3]. In pediatric populations, calcitriol therapy has consistently shown 
effective suppression of bone turnover, though the associated suppression of PTH has been 
much more variable [47-49]. Skeletal results in adult populations have been far less 
congruous. For example, one study in dialysis patients revealed increased BMD at the spine 
and the hip, even though PTH levels were not impacted [50]. Studies have described 
significant reductions in osteoblast surface/bone surface and osteoclast surface/bone surface 
in conjunction with a 73% decrease in PTH [51]. Conversely, other studies have shownno 
difference in these osteoblast/osteoclast parameters associated decrease in PTH [52-53], 
although these studies were not designed to specifically study suppression of PTH to a given 
level. Despite some studies documenting changes in osteoblast and osteoclast surface 
measures, no study has documented differences/changes in the dynamic measures provided 
by fluorescent labeling, further adding to the obscurity. In summary, pediatric populations 
appear to be responsive to calcitriol and its analogues as they exhibit PTH suppression with 
associated changes in dynamic histology parameters. In adults, however, PTH changes are 
much less consistent, and the only histological changes observed are limited static 
parameters. These studies demonstrate the need for a fracture prevention clinical trial with 
calcitriol or its analogs.
In the current study, dynamic measures were consistent with the human studies, though 
osteoclast number and percent surface remained at the level of untreated CKD animals. 
Most importantly, this study showed that calcitriol had no impact on any whole bone 
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mechanical parameters or those assessing bone quality. Unfortunately, none of these 
previous studies revealed clear relationships between bone remodeling and PTH 
suppression. In contrast, by using calcium in the same animal model, we did demonstrate 
efficacy in improving bone histology and CT [29]. However, it is unclear if this was a result 
of increased calcium or more aggressive suppression of PTH. Unfortunately, this approach 
also led to an exacerbation of arterial calcification. Taken together, these data lend support 
to previous suggestions that calcitriol may have a direct effect on bone independent of its 
effect on PTH [46]. Further, because there have been no fracture trials using calcitriol in 
CKD, the extension of its positive effects in patients with osteoporosis [12-13] is simply 
unknown. The future of calcitriol therapy in patients with CKD requires fracture 
assessments for further evaluation. This raises the question of the goal of treatment with 
calcitriol and its analogues.
Our study has some limitations. We do not have baseline biochemistries or bone 
assessments. Previous work in this model shows that at 25 weeks, when we initiated 
treatment in the current study, the biochemistries are roughly comparable with respect to 
calcium and phosphorus, while BUN and PTH are already higher in Cy/+ compared to 
normals [16, 55]. We have not extensively studied the bone phenotype at 25 weeks of age. 
At 20 weeks of age Cy/+ animals already have higher osteoblast and osteoclast surfaces [55] 
without significant alterations in bone mass/geometry or mechanical properties. The current 
experiment was also limited in that only a single dose of calcitriol and a single duration of 
treatment were studied; it is possible that the outcomes would have differed with 
modification of either of these variables. Although we achieved our target goal of 
suppressing PTH by ~50%, which matches the clinical goal of treatment with calcitriol, the 
levels of PTH in our model (12x normal) far exceed those of humans. Most clinical studies 
have excluded patients with very high PTH levels and thus it is possible that the degree of 
hyperparathyroidism, or the severity of hyperphosphatemia could influence the efficacy of 
calcitriol on bone.
The current study demonstrated that calcitriol treatment, while efficacious in terms of PTH 
suppression in animals with CKD, did little to curb the detrimental effects of secondary 
hyperparathyroidism from CKD on the skeleton. This was demonstrated by its lack of effect 
on biochemical, histomorphometric, and most importantly of all mechanical measures. 
Taken together, this indicates that a greater degree of PTH suppression may be required for 
efficacy in skeletal properties to occur in the setting of CKD. Alternatively, there may not be 
efficacy of calcitriol or its analogs on the skeleton. Fracture studies are greatly needed in this 
patient population.
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Figure 1. 
Cancellous bone structure in the proximal tibia and lumbar vertebra as determined by 
microCT. *, p<0.05 compared to NL
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Figure 2. 
Bone formation rates in the proximal tibia and caudal lumbar vertebra as determined by 
dynamic histomorphometry. *, p<0.05 compared to NL
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Figure 3. 
Whole bone mechanical properties of the femur as determined by four-point bending: (a) 
ultimate load, (b) stiffness, and (c) energy to fracture. *, p<0.05 compared to NL
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Table 1
Biochemistry profiles of animals at 30 weeks of age.
Normal CKD (Vehicle) CKD (Calcitriol)
BUN (mg/dL) 14.62 ± 1.95 48.32 ± 8.20 * 43.01 ± 7.07 *
Calcium (mg/dL) 9.979 ± 0.987 11.610 ± 2.323 10.240 ± 1.872
Phosphorus (mg/dL) 4.527 ± 0.579 6.682 ± 2.408 * 7.776 ± 1.170 *
PTH (pg/mL) 181.97 ± 105.05 2194.39 ± 1811.01 * 875.12 ± 432.51 *#
BUN, blood urea nitrogen; PTH, parathyroid hormone
*
vs. Normal;
#
vs. CKD (Vehicle);
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Table 2
Bone architecture and geometry of long bones and vertebra
Proximal Tibia Normal CKD (Vehicle) CKD (Calcitriol)
BV/TV (%) 17.04 ± 3.34 11.26 ± 1.51 * 10.70 ± 1.77 *
Tb.Th (mm) 0.106 ± 0.010 0.108 ± 0.004 0.101 ± 0.005 *
Tb.N (1/mm) 1.611 ± 0.253 1.052 ± 0.150 * 1.057 ± 0.163 *
Tb.Sp (mm) 0.369 ± 0.044 0.604 ± 0.114 * 0.523 ± 0.084 *
Femoral Diaphysis
Ct.Th (mm) 0.876 ± 0.037 0.748 ± 0.056 * 0.769 ± 0.045 *
Ct.Ar (mm2) 8.767 ± 0.631 7.324 ± 0.358 * 7.647 ± 0.378 *
Iap (mm4) 15.00 ± 2.59 12.40 ± 0.58 * 13.19 ± 0.89 *
Iml (mm4) 10.23 ± 1.56 7.50 ± 0.59 * 8.30 ± 0.99 *
Ct.Po (%) 0.690 ± 0.324 0.948 ± 0.401 0.769 ± 0.377
Lumbar Vertebra
BV/TV (%) 41.88 ± 2.92 30.01 ± 3.98 * 29.83 ± 2.88 *
Tb.Th (mm) 0.119 ± 0.004 0.110 ± 0.007 * 0.105 ± 0.008 *
Tb.N (1/mm) 3.581 ± 0.258 2.726 ± 0.324 * 2.823 ± 0.220 *
Tb.Sp (mm) 0.213 ± 0.021 0.280 ± 0.031 * 0.275 ± 0.018 *
Ct.Th (mm) 0.236 ± 0.033 0.170 ± 0.012 * 0.191 ± 0.035 *
*
vs. Normal. BV/TV, bone volume/tissue volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular spacing; Ct.Th, cortical 
thickness; Ct.Ar, cortical area; Iap, moment of inertia in the anterior-posterior direction; Iml, moment of inertia in the medial-lateral direction; 
Ct.Po, cortical porosity.
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Table 3
Trabecular bone histomorphometry
Tibia Normal CKD (Vehicle) CKD (Calcitriol)
MAR (μm/day) 1.305 ± 0.185 2.470 ± 0.569 * 2.285 ± 0.343 *
MS/BS (%) 26.56 ± 5.14 33.32 ± 4.11 35.86 ± 3.26*#
BFR/BS (μm3/μm2/year) 126.65 ± 31.02 299.62 ± 74.35 * 298.51 ± 47.41 *
Oc.S/BS (%) 7.157 ± 1.250 15.739 ± 3.332 * 13.538 ± 2.790 *
N.Oc/BS (1/mm) 1.966 ± 0.412 4.125 ± 0.785 * 3.604 ± 0.590 *
Vertebra
MAR (μm/day) 1.057 ± 0.339 1.983 ± 0.876 * 1.87 ± 0.52 *
MS/BS (%) 13.62 ± 3.98 27.81 ± 5.73 * 31.39 ± 4.58 *
BFR/BS (μm3/μm2/year) 52.14 ± 21.76 211.94 ± 128.49 * 220.61 ± 94.32 *
*
vs. Normal. MAR, mineral apposition rate; MS/BS, mineralizing surface/bone surface; BFR/BS, bone formation rate per bone surface; OcS/BS, 
osteoclast surface per bone surface; N.Oc/BS, number of osteoclasts per bone surface.
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Table 4
Structural and material mechanical properties
Femur Normal CKD (Vehicle) CKD (Calcitriol)
Ultimate Force (N) 272.08 ± 17.75 204.81 ± 23.20 * 214.00 ± 20.04 *
Stiffness (N/mm) 531.67 ± 47.41 412.96 ± 56.28 * 446.99 ± 58.57 *
Energy to Fracture (mJ) 119.16 ± 15.33 91.65 ± 14.13 * 101.305 ± 17.98 *
Ultimate Stress (MPa) 153.81 ± 15.68 143.94 ± 17.93 136.49 ± 9.60
Elastic Modulus (MPa) 4.649 ± 0.633 5.144 ± 0.971 4.830 ± 0.696
Toughness (MPa) 4.336 ± 0.382 3.652 ± 0.545 * 3.815 ± 0.518 *
Vertebra
Ultimate Force (N) 256.89 ± 60.01 187.06 ± 48.03 * 171.31 ± 38.19 *
Stiffness (N/mm) 952.09 ± 314.20 866.74 ± 260.33 845.67 ± 144.32
Energy (mJ) 46.27 ± 10.60 28.05 ± 8.93 * 25.38 ± 10.88 *
Ultimate Stress (MPa) 42.49 ± 10.00 38.74 ± 9.16 35.33 ± 10.88
Elastic Modulus (MPa) 954.37 ± 334.35 1174.00 ± 447.08 1131.84 ± 170.17
Toughness (MPa) 1.310 ± 0.470 0.924 ± 0.347 0.819 ± 0.386
*
vs. Normal
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Table 5
Bone Quality
Raman Spectroscopy Normal CKD (Vehicle) CKD (Calcitriol)
Crystallinity (1/FWHM
PO43-ν1)
0.0529 ± 0.0003 0.0534 ± 0.0008 0.0534 ± 0.0004
Carbonate Substitution
(CO32-ν1/ PO43-ν1)
0.247 ± 0.008 0.242 ± 0.013 0.238 ± 0.013
Relative Mineralization
(PO43-ν1/Amide I)
2.598 ± 0.341 2.403 ± 0.442 2.759 ± 0.299
Nanoindentation
Elastic Modulus (GPa) 11.066 ± 2.766 9.666 ± 1.021 9.987 ± 2.610
Hardness (MPa) 202.62 ± 22.86 192.68 ± 47.35 209.426 ± 43.65
Am J Nephrol. Author manuscript; available in PMC 2017 February 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Newman et al. Page 22
Ta
bl
e 
6
Su
m
m
ar
y 
of
 p
re
-c
lin
ic
al
 a
ss
es
sm
en
t o
f c
al
ci
tri
ol
 (a
nd
 an
alo
gs
) o
n b
on
e p
rop
ert
ies
.
R
ef
er
en
ce
A
ni
m
al
M
od
el
Ba
se
lin
e
fo
ld
in
cr
ea
se
 in
PT
H
in
 u
re
m
ic
 v
s
n
o
rm
a
l
Tr
ea
tm
en
t
Pe
rc
en
t
ch
an
ge
 in
PT
H
 w
ith
tr
ea
tm
en
t
Bo
ne
 H
ist
om
or
ph
om
et
ry
 r
es
po
ns
e
to
 tr
ea
tm
en
t
C
T 
(b
on
e
v
o
lu
m
e 
or
di
am
et
er
)
re
sp
on
se
 to
tr
ea
tm
en
t
M
ec
ha
ni
cs
Tu
rn
ov
er
a
M
in
er
al
i-z
at
io
nb
V
ol
um
ec
Ja
bl
on
sk
i
19
95
5/
6t
h  
N
X
ra
ts
 o
ut
 4
m
o
n
th
s
fro
m
su
rg
er
y
1.
2X
Ca
lc
itr
io
l
0.
17
μg
/1
00
 g
B
W
 d
ai
ly
 fo
r 1
2
w
ee
ks
N
ot
ch
an
ge
d
N
ot
 d
on
e,
bu
t s
ta
tic
er
o
de
d
su
rfa
ce
im
pr
ov
ed
↑
↑
↑
↑ S
tif
fn
es
s
↑ T
im
e 
to
 fr
ac
tu
re
N
S 
To
ug
hn
es
s
Jo
ki
ha
ar
a
20
06
5/
6t
h  
N
X
ra
ts
 o
ut
 1
6
w
ee
ks
 fr
om
su
rg
er
y
13
.0
X
Pa
ric
al
ci
to
l 1
00
n
g/
ra
t 3
 ti
m
es
pe
r w
ee
k 
fo
r 1
2
w
ee
ks
↓6
1%
N
A
N
A
N
A
↑
↑ U
lti
m
at
e 
lo
ad
 a
t f
em
or
al
 n
ec
k
N
S 
U
lti
m
at
e 
lo
ad
 a
t f
em
or
al
di
ap
hy
sis
N
av
es
-D
ia
z
20
07
7/
8 
N
x,
st
ar
te
d
tr
ea
tm
en
t 1
w
ee
k 
la
te
r
N
o 
no
rm
al
an
im
al
s
Ca
lc
itr
io
l 1
0
n
g/
kg
 B
W
 5
tim
es
 p
er
 w
ee
k
fo
r 8
 w
ee
ks
↓3
8%
La
be
ls 
to
o
w
ea
k
N
S
↑
N
A
N
A
Fi
nc
h 
20
10
5/
6t
h  
N
x
st
ar
te
d
tr
ea
tm
en
t
w
he
n
“
u
re
m
ic
”
9.
27
X
Pa
ric
al
ci
to
l
0.
16
 u
g/
kg
 B
W
th
re
e 
tim
es
 p
er
w
ee
k 
fo
r 6
w
ee
ks
↓4
9%
N
S
N
S
↓
N
A
N
A
N
ew
m
an
(cu
rre
nt
st
ud
y)
Cy
/+
sp
on
ta
ne
ou
s 
CK
D
 ra
t
12
X
Ca
lc
itr
io
l 1
0
n
g/
kg
 B
W
 3
tim
es
 p
er
 w
ee
k
fo
r 5
 w
ee
ks
↓6
0%
N
S
N
S
N
S
N
S
N
S 
(U
ltim
ate
 fo
rce
, s
tif
fne
ss,
en
er
gy
 to
 fr
ac
tu
re
, u
lti
m
at
e
st
re
ss
, e
la
sti
c 
m
od
ul
es
,
to
ug
hn
es
s i
n 
bo
th
 fe
m
ur
di
ap
hy
sis
 a
nd
 v
er
te
br
a)
N
x 
= 
ne
ph
re
ct
om
y;
 F
N
 =
 fe
m
or
al
 n
ec
k,
 C
T=
 m
ic
ro
CT
 (a
nim
als
) o
r D
XA
 (D
ua
l X
ray
 A
bs
orp
tio
me
try
↑=
 im
pr
ov
es
 w
ith
 tr
ea
tm
en
t; 
↓ =
 w
o
rs
en
s 
w
ith
 tr
ea
tm
en
t; 
N
S 
= 
no
t s
ta
tis
tic
al
ly
 d
iff
er
en
t f
ro
m
 u
re
m
ic
 c
on
tro
ls)
; N
A 
= n
ot 
av
ail
ab
le
a
=
 b
on
e 
fo
rm
at
io
n 
ra
te
, m
in
er
al
 a
pp
os
iti
on
 ra
te
;
b =
 M
in
er
al
iz
in
g 
su
rfa
ce
/b
on
e 
su
rfa
ce
 (M
S/B
S)
 or
 os
teo
id 
vo
lum
e;
c =
 b
on
e 
vo
lu
m
e/
 to
ta
l v
ol
um
e
Am J Nephrol. Author manuscript; available in PMC 2017 February 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Newman et al. Page 23
Ta
bl
e 
7
Su
m
m
ar
y 
of
 c
lin
ic
al
 a
ss
es
sm
en
t o
f c
al
ci
tri
ol
 (a
nd
 an
alo
gs
) o
n b
on
e p
rop
ert
ies
.
R
ef
er
en
ce
Pa
tie
nt
ch
ar
ac
te
ri
st
ic
s
Tr
ea
tm
en
t
Bo
ne
 H
ist
om
or
ph
om
et
ry
 r
es
po
ns
e 
to
 tr
ea
tm
en
t
D
X
A
Fr
ac
tu
re
Tu
rn
ov
er
a
M
in
er
al
iz
at
io
n
b
V
ol
um
ec
B
ak
er
 1
98
6
54
 p
at
ie
nt
s a
t b
as
el
in
e,
20
 fo
llo
w
 u
p 
bo
ne
bi
op
sie
s i
n 
pa
tie
nt
s w
ith
CK
D
 3
-5
 n
ot
 E
SR
D
O
ra
l c
al
ci
tri
ol
 v
s. 
pl
ac
eb
o 
12
 to
57
 m
on
th
s o
f t
re
at
m
en
t
N
o 
dy
na
m
ic
 la
be
lin
g;
w
o
rs
en
ed
 in
 5
0%
 o
f p
la
ce
bo
;
40
%
 o
f c
al
ci
tri
ol
 (1
0%
 hi
gh
er;
30
%
 v
er
y 
lo
w
)
W
or
se
ne
d 
in
40
%
 p
la
ce
bo
an
d 
30
%
 o
f
ca
lc
itr
io
l
H
am
dy
19
95
13
4 
pa
tie
nt
s w
ith
 C
K
D
3-
5 
no
t E
SR
D
O
ra
l a
lfa
ca
lc
id
ol
 v
s. 
pl
ac
eb
o 
fo
r
24
 m
on
th
s
Im
pr
ov
ed
 in
 3
2%
, w
or
se
ne
d
in
 1
1%
 o
f a
lfa
ca
lc
id
ol
;
pl
ac
eb
o 
gr
ou
p 
im
pr
ov
ed
 in
3%
 a
nd
 w
or
se
ne
d 
in
 1
3%
Im
pr
ov
ed
 in
al
fa
ca
lc
id
ol
tr
ea
tm
en
t
N
S
N
or
da
l 1
98
8
30
 p
at
ie
nt
s w
ith
 C
K
D
 3
-
5 
no
t E
SR
D
28
 p
ts 
w
ith
 b
io
ps
y 
af
te
r p
la
ce
bo
o
r 
ca
lc
itr
io
l f
or
 8
 m
on
th
s
M
ea
n 
B
FR
 d
ec
re
as
ed
 in
ca
lc
itr
io
l, 
in
cr
ea
se
d 
in
pl
ac
eb
o.
 2
5%
 o
f t
he
 ca
lc
itr
io
l
pa
tie
nt
s h
ad
 to
o 
lo
w
 B
FR
Sa
lu
sk
y
19
98
46
 ch
ild
re
n 
on
pe
rit
on
ea
l d
ia
ly
sis
IP
 v
s. 
PO
 c
al
ci
tri
ol
 fo
r 1
2 
m
on
th
s
IP
 c
al
ci
tri
ol
: 4
4%
 lo
w
er
; 3
7%
to
o 
lo
w
PO
 c
al
ci
tri
ol
 in
cr
ea
se
d 
in
12
%
, l
ow
er
ed
 in
 2
3%
; t
oo
 lo
w
in
 2
9%
W
es
se
lin
g-
Pe
rr
y 
20
11
60
 ch
ild
re
n 
on
pe
rit
on
ea
l d
ia
ly
sis
PO
 c
al
ci
tri
ol
 v
s. 
do
xe
rc
al
ci
fe
ro
l;
in
 e
ac
h 
gr
ou
p 
se
ve
la
m
er
 o
r
ca
lc
iu
m
 a
s p
ho
sp
ha
te
 b
in
de
r
B
FR
 ↓ 
in
 a
ll 
4 
gr
ou
ps
; 7
2%
ac
hi
ev
ed
 N
L 
BF
R;
 o
nl
y 
1 
pt
ha
d 
ve
ry
 lo
w
 B
FR
↓
N
S
Pr
ze
dl
ac
ki
19
95
25
 p
at
ie
nt
s w
ith
 C
K
D
st
ag
es
 4
-5
PO
 c
al
ci
tri
ol
 v
s. 
pl
ac
eb
o 
fo
r 1
2
m
o
n
th
s
↑
R
ix
 1
99
9
11
3 
pa
tie
nt
s w
ith
 C
K
D
st
ag
es
 4
-5
A
lfa
ca
lc
id
ol
 v
s. 
pl
ac
eb
o 
fo
r 1
2
m
o
n
th
s
↑
↑=
 im
pr
ov
es
 w
ith
 tr
ea
tm
en
t; 
↓ =
 w
o
rs
en
s 
w
ith
 tr
ea
tm
en
t; 
N
S 
= 
no
t s
ta
tis
tic
al
ly
 d
iff
er
en
t f
ro
m
 c
on
tro
ls;
 b
la
nk
 c
el
l =
 n
ot
 d
on
e
a
=
 b
on
e 
fo
rm
at
io
n 
ra
te
 (B
FR
), m
ine
ral
 ap
po
sit
ion
 ra
te;
b =
 M
in
er
al
iz
in
g 
su
rfa
ce
/b
on
e 
su
rfa
ce
 (M
S/B
S)
 or
 os
teo
id 
vo
lum
e;
c =
 b
on
e 
vo
lu
m
e/
 to
ta
l v
ol
um
e
Am J Nephrol. Author manuscript; available in PMC 2017 February 17.
